Shares of InMed Pharmaceuticals INM surged 36.33% at market close after the company announced the launch of its neurodegenerative disease program (INM-900 series), to investigate the effects of ...
InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease
InMed Pharmaceuticals (Nasdaq:INM) recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s ...
Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or ...
When it comes to treating degenerative diseases like Alzheimer’s, much of the current focus is on addressing the symptoms rather than repairing and regenerating the damaged tissues and cells. Some ...
Planning is underway for the next stage of advanced preclinical studies and will include drug metabolism and pharmacokinetics as well as initiation of pharmaceutical drug development activities such ...
InMed Pharmaceuticals Inc. (NASDAQ:INM) stock is surging early Tuesday, with a session volume of 6.63 million compared to the average volume of 1.31 million, as per data from Benzinga Pro. On Tuesday, ...
InMed Pharmaceuticals Inc (NASDAQ:INM) shares are trading higher by 22.6% to $6.05 during Tuesday’s session after the company announced that INM-901 reduced Alzheimer’s-related inflammation in a ...
InMed Pharmaceuticals Inc. Annual stock financials by MarketWatch. View the latest INM financial statements, income statements and financial ratios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results